Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacology, M...
Saved in:
Main Authors: | Liao MZ (Author), Kast J (Author), Berkhout M (Author), Prenen H (Author), Dutta S (Author), Upreti VV (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
by: Hendrikx JJMA, et al.
Published: (2020) -
Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021) -
Flat dose regimen of toripalimab based on model-informed drug development approach
by: Lili Li, et al.
Published: (2023) -
Dose-response association between maternal pre-pregnancy bodyweight and gestational diabetes mellitus following ART treatment: a population-based cohort study
by: Yiquan Xiong, et al.
Published: (2022) -
Effect of migrant parents' bodyweight perception on children's body bodyweight: A longitudinal analysis of population cohort study
by: Susan Hartono, et al.
Published: (2023)